Mitogen-Activated Protein Kinase Inhibitors and T-Cell-Dependent Immunotherapy in Cancer

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 13; no. 1; p. 9
• Main Authors: Kumar, Sandeep, Principe, Daniel R, Singh, Sunil Kumar, Viswakarma, Navin, Sondarva, Gautam, Rana, Basabi, Rana, Ajay
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 07.01.2020; MDPI
• Subjects: Apoptosis; cancer; cytotoxic t-lymphocyte-associated protein 4; Immunotherapy; Kinases; mitogen-activated protein kinase; programmed cell death protein 1; programmed death-ligand 1; Review; t cells; t-cell anergy; Tumor necrosis factor-TNF; mitogen-activated protein kinase; Programmed death-ligand 1; cytotoxic T-lymphocyte-associated protein 4; immunotherapy; Programmed cell death protein 1; T-cell anergy; cancer; T cells
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph13010009

Mitogen-activated protein kinase (MAPK) signaling networks serve to regulate a wide range of physiologic and cancer-associated cell processes. For instance, a variety of oncogenic mutations often lead to hyperactivation of MAPK signaling, thereby enhancing tumor cell proliferation and disease progression. As such, several components of the MAPK signaling network have been proposed as viable targets for cancer therapy. However, the contributions of MAPK signaling extend well beyond the tumor cells, and several MAPK effectors have been identified as key mediators of the tumor microenvironment (TME), particularly with respect to the local immune infiltrate. In fact, a blockade of various MAPK signals has been suggested to fundamentally alter the interaction between tumor cells and T lymphocytes and have been suggested a potential adjuvant to immune checkpoint inhibition in the clinic. Therefore, in this review article, we discuss the various mechanisms through which MAPK family members contribute to T-cell biology, as well as circumstances in which MAPK inhibition may potentiate or limit cancer immunotherapy.